Get started
Author

Sachiko Kawana

Observed names: S Kawana, S. Kawana
ORCID: 0000-0001-7146-6949
Observed ORCID: 0000-0001-7146-6949
OpenAlex ID: A5080896248
Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
2018 · Yukihiro Toi, Shunichi Sugawara, et al. · JAMA Oncology · 359
PDF
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab
2018 · Yukihiro Toi, Shunichi Sugawara, et al. · The Oncologist · 299
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer
2019 · Mari Aso, Yukihiro Toi, et al. · The Oncologist · 58
PDF
Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab
2019 · Jun Sugisaka, Yukihiro Toi, et al. · JMA Journal · 25
Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia
2024 · Yuki Kato, Hibiki Udagawa, et al. · Lung Cancer · 24
PDF
Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer
2021 · Kana Ono, Hirotaka Ono, et al. · Cancer Medicine · 21
Suppression of tumor immune microenvironment via microRNA‐1 after epidermal growth factor receptor‐tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma
2020 · Sachiko Kawana, Ryoko Saito, et al. · Cancer Medicine · 17
PDF
Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers
2021 · Tomoiki Aiba, Chieko Hattori, et al. · PLoS ONE · 11
PDF
Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study.
2019 · Yukihiro Toi, Yuichiro Kimura, et al. · Sarcoidosis vasculitis and diffuse lung diseases · 10
PDF
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial
2024 · Ryota Shibaki, Daichi Fujimoto, et al. · Lung Cancer · 7
Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
2019 · J. Sugisaka, S. Sugawara, et al. · Annals of Oncology · 4
PDF
Two Cases of Acute Respiratory Distress Syndrome with High Values of Chlamydophila pneumoniae-Specific Antibodies
2013 · Ryotaro Igusa, Atsushi Nakamura, et al. · Internal Medicine · 3
PDF
Real-world outcomes and association between immune-related adverse events and therapeutic efficacy of nivolumab plus ipilimumab in elderly patients (≥75 years) with advanced non-small cell lung cancer
2025 · Soichiro Minami, Tsuyoshi Doman, et al. · Translational Lung Cancer Research · 2
Guess what! Diagnosis and comments: Birt-Hogg-Dubé syndrome.
2000 · M Aoki, S Kawana · European Journal of Dermatology · 2
Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge
2023 · Jun Sugisaka, Yukihiro Toi, et al. · Thoracic Cancer · 1
PDF
P1.16-29 Profiling Immune-Related Adverse Events (irAEs) in Patients with Anti-PD-1 for Advanced Non-Small Cell Lung Cancer
2019 · Y. Toi, S. Sugawara, et al. · Journal of Thoracic Oncology · 1
A Case of Pseudoprogression in Lung Adenocarcinoma Treated with Nivolumab
2019 · Atsushi Nakamura, Tomoiki Aiba, et al. · Haigan · 1
PDF
P2.07-004 Immune-Related Adverse Events (irAEs) of Nivolumab Predicts Clinical Benefit in Advanced Lung Cancer Patients
2017 · Y. Toi, S. Sugawara, et al. · Journal of Thoracic Oncology · 1
Successful application of whole-liver irradiation in a patient with small cell lung cancer with diffuse liver metastasis: a case report
2026 · Takahiro Ogasawara, Yukihiro Toi, et al. · Journal of Medical Case Reports
Immune checkpoint inhibitor rechallenge in advanced NSCLC: prognostic value of the neutrophil-to-lymphocyte ratio
2026 · Soichiro Minami, Yusuke Yamazaki, et al. · Translational Lung Cancer Research
A case of lower respiratory tract infection caused by Pandoraea sputorum in a human T-lymphotropic virus type 1 carrier
2025 · Takahiro Ogasawara, Shinsuke Yamanda, et al. · IDCases
522P Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
2023 · I. Nakachi, D. Fujimoto, et al. · Annals of Oncology
PDF
Single-sample enrichment analysis identified predictive biomarker candidates for nivolumab in patients with non-small cell lung cancer.
2021 · Tomoiki Aiba, Chieko Hattori, et al. · Journal of Clinical Oncology
P1.16-34 Association Between Skin Reactions and Clinical Benefit in Patients Treated with Anti-PD-1 Treatment for Advanced Non-Small Cell Lung Cancer
2019 · M. Aso, S. Sugawara, et al. · Journal of Thoracic Oncology
PDF
Profiling of immune related adverse events from nivolumab or pembrolizumab monotherapy in advanced non-small cell lung cancer in real world
2018 · M. Aso, S. Sugawara, et al. · Annals of Oncology
Works count: 26
Citation count: 845
H-index: 9
I10-index: 9
Year
Topic
Type